Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
Chunyan Luan, Baoan ChenDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province 210009, People’s Republic of ChinaCorrespondence: Baoan ChenDepartment of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhong...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2019-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_61a7e28d2e534cb4a878d7b36d8a92fe | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Luan C |e author |
| 700 | 1 | 0 | |a Chen B |e author |
| 245 | 0 | 0 | |a Clinical application of obinutuzumab for treating chronic lymphocytic leukemia |
| 260 | |b Dove Medical Press, |c 2019-08-01T00:00:00Z. | ||
| 500 | |a 1177-8881 | ||
| 520 | |a Chunyan Luan, Baoan ChenDepartment of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu Province 210009, People’s Republic of ChinaCorrespondence: Baoan ChenDepartment of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, School of Medicine, Southeast University, Dingjiaqiao 87, Gulou District, Nanjing, Jiangsu Province 210009, People’s Republic of ChinaTel +86 258 327 2006Fax +86 258 327 2011Email cba8888@hotmail.comAbstract: Alkylators and nucleoside analogs were the main drugs for treatingchronic lymphoblastic leukemia (CLL), which have been replaced by monoclonal antibodies, such as rituximab in the past 10 years for refractory or relapsed CLL. The first-line immunochemotherapy regimen, rituximab combined with nucleoside analogs, significantly increased CLL patients’ first-reaction rate and improved progression-free survival. Despite the long-lasting remissions by the use of chemoimmunotherapy, most CLL patients will relapse eventually. The obinutuzumab (GA101), an updated CD20 antibody, that is thought to achieve a more durable response with unique molecular and functional characteristics. Obinutuzumab is a humanized, monoclonal type II CD20 antibody modified by glycoengineering. The glycoengineered Fc portion enhances the binding affinity to the FcγRIII receptor on immune effector cells, resulting in increased antibody-dependent cellular cytotoxicity and phagocytosis. In addition, the type II antibody binding characteristics of obinutuzumab to CD20 lead to an efficient induction of direct non-apoptotic cell death. This review summarizes the results of clinical studies using obinutuzumab and looks forward to its further application in treating CLL clinically.Keywords: CD20 antibody, GA101, obinutuzumab, chronic lymphocytic leukemia | ||
| 546 | |a EN | ||
| 690 | |a CD20 antibody | ||
| 690 | |a GA101 | ||
| 690 | |a obinutuzumab | ||
| 690 | |a chronic lymphocytic leukemia | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Drug Design, Development and Therapy, Vol Volume 13, Pp 2899-2909 (2019) | |
| 787 | 0 | |n https://www.dovepress.com/clinical-application-of-obinutuzumab-for-treating-chronic-lymphocytic--peer-reviewed-article-DDDT | |
| 787 | 0 | |n https://doaj.org/toc/1177-8881 | |
| 856 | 4 | 1 | |u https://doaj.org/article/61a7e28d2e534cb4a878d7b36d8a92fe |z Connect to this object online. |